Phase 3 clinical trial
Biotech Sector Snapshot: Trial Failure Meets a Rally
One failed trial erased more than a billion dollars from a single biotech’s market value this week. The sector it trades in barely noticed. Both of those facts are true at the same time, and untangling why is more useful than picking a single winner to write about. The Rally’s Math: XBI Up 36% Even…
OmniAb Jumps 13% on Eli Lilly Ion Channel Collaboration
OmniAb landed a partner with deep pockets on Monday. Acurx Pharmaceuticals landed something smaller but just as telling: a brand name regulators are willing to put on a drug label. Neither event is an approval. Both moved the stock like one. OmniAb Jumps 13% on Eli Lilly Collaboration Worth Up to $370 Million OmniAb (Nasdaq:…
Intellia Stock Rises on FDA Clearance for CRISPR Therapy
NTLA performance by TradingView Intellia Therapeutics (NASDAQ: NTLA) saw shares rise after the FDA lifted a clinical hold on one of its Phase 3 trials for nexiguran ziclumeran (nex-z), a CRISPR-based therapy for transthyretin amyloidosis (ATTR). What Happened Last October, U.S. regulators paused two trials after a participant died from severe liver toxicity. The cleared…
